Browse Category

NYSE:PFE News 22 June 2025 - 2 October 2025

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Market commentary and outlook Lara Castleton of Janus Henderson noted that Tuesday’s White House–Pfizer announcement “was the catalyst for healthcare,” freeing up investors to rotate into the beaten-down sector reuters.com. Kyle Rodda at Capital.com observed that the weak ADP report “suggests the U.S. economy is in almost dire need for further policy support,” so markets are pricing in much higher odds of Fed rate cuts in October and December reuters.com. He added that “after some initial jitters, markets shrugged off the U.S. government shutdown, at least for now,” since past shutdowns have had “trivial” market impact reuters.com. Analysts are watching
2 October 2025
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Share Price & Recent Performance In early September 2025, Pfizer (NYSE:PFE) was trading in the mid–$20 range. After a relatively quiet first weeks of the month, the stock exploded higher at month-end. On Sept. 30, PFE closed at $25.48 after soaring ~6.8% that day investing.com. The rally continued on Oct. 1, with PFE closing at $27.21 (another +6.8%) investing.com. In total, Pfizer climbed roughly 15% in the five trading days Sept 26–Oct 1. By contrast, Pfizer had been about flat in August–September, hovering in the low $24s prior to this surge. The late-month gains reflect investor excitement over the Trump pricing deal and positive
Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Overview Index Performance The 1 October 2025 session began under a cloud as the federal government shut down due to a budget impasse. Stock futures opened lower amid fears that key economic reports might be delayed investopedia.com. By the closing bell, however, Wall Street had staged a dramatic recovery: Contrary to midday reports that the S&P 500 and Nasdaq 100 were modestly negative due to a risk‑off mood nasdaq.com, late‑day buying pushed all major indices into positive territory. Market breadth improved: the S&P 500 recorded 37 new 52‑week highs versus 7 lows, while the Nasdaq tallied 111 highs and 68 lows reuters.com. Sector
Stocks Rally to Record Highs as Shutdown Looms – Dow and S&P Post Best September in 15 Years

Stocks Rally to Record Highs as Shutdown Looms – Dow and S&P Post Best September in 15 Years

Market Performance (Sept. 30 & Oct. 1) U.S. stock markets closed Sept. 30 higher, ending the month on a positive note. The S&P 500 closed at 6,688.46 (+0.41%), the Dow at 46,397.89 (+0.18%), and the Nasdaq at 22,660.01 (+0.31%) reuters.com. All three indices notched monthly and quarterly gains: for September, the S&P rose about 3.5% (its best September since 2010) reuters.com reuters.com, and the Dow and Nasdaq each notched their largest one-month rise since 2019. This pushed the Dow to another record closing high reuters.com. Defensive sectors (health care, consumer staples, utilities) outperformed, while cyclical areas (airlines, transports) lagged due
1 October 2025
Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

What Is “TrumpRx”? A Direct-to-Consumer Drug Website “TrumpRx” is a planned federal website that will let Americans buy prescription medicines directly from the government at cash prices. According to administration officials, TrumpRx will negotiate discounted rates with drugmakers and allow patients to pay out-of-pocket for certain drugs, bypassing insurers and middlemen wbtv.com reuters.com. White House Press Secretary Karoline Leavitt confirmed on social media that Trump will announce TrumpRx, and a Wall Street Journal report says the site will be branded TrumpRx newsweek.com reuters.com. It is not yet clear which medications will be offered, but the idea is to force prices
30 September 2025
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

Stock Performance (Sep 2025) On Sept 30, 2025 Pfizer closed around $24.40 reuters.com. Over the past year PFE underperformed the pharma sector (latest 52-week range ~$20.91–30.43 reuters.com). Its trailing P/E is 12.64× reuters.com (ex. special items) and forward P/E ~7.7× reuters.com, compared to ~19× for J&J and ~12× for Merck (see table). Pfizer’s dividend yield (~7.2%) reuters.com is by far the highest in big pharma (JNJ ~2.9%, MRK ~4.1%). The stock rallied on strong earnings in early August s206.q4cdn.com reuters.com and on the Sept 30 Trump pricing news. Q2 2025 Financial Results and Corporate Updates Pfizer reported Q2 2025 revenue
Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Industry & Corporate Developments Mergers, Acquisitions & Partnerships Regulatory & Drug Approval Updates Public Health & Policy Research & Clinical Breakthroughs Sources: Reuters, Politico, HealthLeaders, BioPharma Dive, FierceBiotech, Pharmaceutical Executive, Technology Networks, McGill University reuters.com reuters.com healthleadersmedia.com reuters.com fiercebiotech.com reuters.com reuters.com technologynetworks.com technologynetworks.com.
21 August 2025
Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

New Drug Approvals & Clinical Trial Results Mergers, Acquisitions & Partnerships (No other major M&A deals were announced during Aug 17–18, but this Lilly-Superluminal alliance highlights the continued investment in AI-driven R&D.) Regulatory & Policy Updates Public Health & Epidemiology (No major new COVID-19 variant or pandemic threat emerged over the weekend, but health officials continue to monitor familiar foes like measles, polio, and others as vaccination lapses threaten to reverse public health gains.) Scientific & Medical Breakthroughs (Additional notable research: Other studies this week reported that a simple walking gait adjustment can ease knee arthritis as much as medication,
18 August 2025
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy (semaglutide) received FDA accelerated approval to treat metabolic dysfunction-associated steatohepatitis (MASH), becoming the first GLP-1 therapy cleared for MASH in a patient population estimated at about 5% of U.S. adults, based on part 1 of an ongoing trial showing liver health improvement. Tonix Pharmaceuticals’ Tonmya, or TNX-102 SL, was approved August 15 for fibromyalgia, the first new fibromyalgia therapy in 15 years, with two Phase 3 trials showing significantly reduced daily pain versus placebo at 14 weeks and a potential peak U.S. sales of about $800 million. Pfizer’s inclacumab, a P-selectin inhibitor acquired via the 2022 $5.4 billion Global
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Pfizer Inc., in collaboration with BioNTech, co-developed the first FDA-approved mRNA COVID-19 vaccine, Comirnaty. Roche Holding AG is the world’s largest biotech company and a leader in oncology treatments (Herceptin) and diagnostics. Moderna, Inc. pioneered mRNA vaccine technology and its COVID-19 vaccine was among the first mRNA medicines approved, while expanding mRNA therapeutics for cancer and rare diseases. Illumina, Inc. is a market leader in DNA sequencing with platforms such as NovaSeq that enabled the concept of a $1,000 genome. CRISPR Therapeutics AG is a leading CRISPR-Cas9 gene editing company developing exa-cel for sickle cell disease and other therapies. Ginkgo
Go toTop